Valuation: 4D Molecular Therapeutics, Inc.

Market Cap 799M 703M 665M 603M 1.13B 76.73B 1.14B 7.96B 3.07B 39.16B 3B 2.94B 126B P/E 2026 *
-3.53x
P/E 2027 * -3.63x
Enterprise Value 604M 531M 503M 456M 856M 58B 861M 6.02B 2.32B 29.6B 2.27B 2.22B 95.11B EV / Sales 2026 *
47.3x
EV / Sales 2027 * 21.9x
Free-Float
97.07%
Yield 2026 *
-
Yield 2027 * -
1 day-0.52%
1 week-4.72%
Current month+2.91%
1 month-1.02%
3 months+12.73%
6 months+69.43%
Current year+93.60%
1 week 13.56
Extreme 13.56
16.23
1 month 12.94
Extreme 12.94
16.23
Current year 6.96
Extreme 6.96
16.93
1 year 6.96
Extreme 6.96
16.93
3 years 2.24
Extreme 2.235
36.25
5 years 2.24
Extreme 2.235
36.25
10 years 2.24
Extreme 2.235
55.11
Manager TitleAgeSince
Chief Operating Officer 51 2018-03-31
Chief Executive Officer 64 2013-09-11
Director of Finance/CFO 51 2025-11-16
Director TitleAgeSince
Chairman 64 2013-09-11
Director/Board Member 62 2015-11-30
Director/Board Member 47 2019-02-28
Date Insider Type Main position Quantity % Market Cap. Importance
9/16/26 Exercice

Compliance Officer

4,905 0.0089%
9/14/26 Sell

Founder

-58,333 0.1056%
9/1/26 Exercice

Compliance Officer

1,752 0.0032%
Change 5-day change 1-year change 3-year change Capi.($)
-0.52%-4.72%+73.89%+14.87% 799M
+2.64%+6.45%+12.39%+38.40% 47.97B
+0.74%+0.84%+50.59%+37.66% 44.5B
-0.77%+5.65%+342.04%+621.14% 43.93B
+1.59%+0.21%+10.09%+98.96% 41.03B
+0.51%-0.61%+5.18%+46.87% 29.85B
-0.33%-1.23%+23.11%+150.24% 17.27B
+0.19%+8.93%+8.18% - 15.34B
+1.76%+0.85%+29.47%+48.42% 15.3B
+1.99%-2.71% - - 14.82B
Average +0.75%+1.72%+61.66%+132.07% 27.08B
Weighted average by Cap. +0.90%+2.95%+76.08%+164.60%

Financials

2026 *2027 *
Net sales 12.77M 11.23M 10.62M 9.63M 18.09M 1.23B 18.19M 127M 49.1M 625M 47.93M 46.89M 2.01B 21.2M 18.65M 17.63M 15.99M 30.03M 2.04B 30.21M 211M 81.53M 1.04B 79.59M 77.87M 3.34B
Net income -290M -255M -241M -219M -410M -27.81B -413M -2.88B -1.11B -14.19B -1.09B -1.06B -45.6B -319M -281M -265M -241M -452M -30.63B -455M -3.18B -1.23B -15.63B -1.2B -1.17B -50.22B
Net Debt -195M -172M -162M -147M -276M -18.73B -278M -1.94B -751M -9.56B -733M -717M -30.72B -334M -294M -278M -252M -473M -32.07B -476M -3.33B -1.28B -16.36B -1.25B -1.23B -52.59B
Logo 4D Molecular Therapeutics, Inc.
4D Molecular Therapeutics, Inc. is a late-stage biotechnology company advancing durable and disease-targeted therapeutics. The Company's lead product candidate 4D-150 is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) with a single, safe, intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections. Its lead indication for 4D-150 is wet age-related macular degeneration, which is in Phase III development, and second indication is diabetic macular edema. The Company is developing 4D-710 for the treatment of a range of people with cystic fibrosis independent of their specific CFTR mutation. 4D-710 is an investigational genetic medicine candidate using the A101 vector for the treatment of cystic fibrosis lung disease. The Company's non-core programs include 4D-175, 4D-725, and 4D-310.
Employees
196
Date Price Change Volume
26-09-28 US$14.52 +0.35% 1,124,314
26-09-25 US$14.47 -1.63% 1,018,004
26-09-24 US$14.71 -1.93% 1,768,229
26-09-23 US$15.00 -5.54% 1,465,465
26-09-22 US$15.88 +4.20% 936,969
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
14.47USD
Average target price
28.18USD
Spread / Average Target
+94.76%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. FDMT Stock